Agenus Inc (AGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Agenus Inc (AGEN) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.74 Million) by net assets ($-280.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Agenus Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Agenus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AGEN total liabilities for a breakdown of total debt and financial obligations.
Agenus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agenus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GR Silver Mining Ltd
V:GRSL
|
-0.145x |
|
Sunfon Construction Co Ltd
TWO:5514
|
-0.056x |
|
YTN Co.Ltd
KQ:040300
|
-0.005x |
|
KPS Corporation
KQ:256940
|
-0.036x |
|
Suria Capital Holdings Bhd
KLSE:6521
|
-0.009x |
|
Land General Bhd
KLSE:3174
|
0.074x |
|
SLOMAN NEPTUN Schiffahrts-Aktiengesellschaft
HM:NEP
|
0.068x |
|
Chung Lien Transportation Co Ltd
TWO:5604
|
0.011x |
Annual Cash Flow Conversion Efficiency for Agenus Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Agenus Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Agenus Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-306.42 Million | $-158.31 Million | 0.517x | -65.81% |
| 2023-12-31 | $-148.38 Million | $-224.20 Million | 1.511x | -52.70% |
| 2022-12-31 | $-54.90 Million | $-175.37 Million | 3.194x | +1408.48% |
| 2021-12-31 | $47.91 Million | $10.14 Million | 0.212x | -67.80% |
| 2020-12-31 | $-211.50 Million | $-139.10 Million | 0.658x | +714.39% |
| 2019-12-31 | $-231.34 Million | $-18.68 Million | 0.081x | -89.25% |
| 2018-12-31 | $-174.55 Million | $-131.09 Million | 0.751x | -39.57% |
| 2017-12-31 | $-75.82 Million | $-94.23 Million | 1.243x | -39.19% |
| 2016-12-31 | $-39.13 Million | $-79.96 Million | 2.044x | +406.40% |
| 2015-12-31 | $70.73 Million | $-47.18 Million | -0.667x | +59.85% |
| 2014-12-31 | $23.02 Million | $-38.23 Million | -1.661x | -138.11% |
| 2013-12-31 | $-4.48 Million | $-19.53 Million | 4.359x | +5274.33% |
| 2012-12-31 | $-12.02 Million | $1.01 Million | -0.084x | -110.80% |
| 2011-12-31 | $-20.83 Million | $-16.25 Million | 0.780x | -22.26% |
| 2010-12-31 | $-14.71 Million | $-14.76 Million | 1.003x | -29.59% |
| 2009-12-31 | $-16.98 Million | $-24.19 Million | 1.425x | +17.91% |
| 2008-12-31 | $-23.92 Million | $-28.91 Million | 1.209x | +113.12% |
| 2007-12-31 | $-47.06 Million | $-26.69 Million | 0.567x | -78.05% |
| 2006-12-31 | $-17.39 Million | $-44.94 Million | 2.584x | +224.26% |
| 2005-12-31 | $31.90 Million | $-66.33 Million | -2.079x | -267.49% |
| 2004-12-31 | $106.44 Million | $-60.22 Million | -0.566x | -16.33% |
| 2003-12-31 | $105.25 Million | $-51.19 Million | -0.486x | +25.60% |
| 2002-12-31 | $77.76 Million | $-50.83 Million | -0.654x | -34.79% |
| 2001-12-31 | $75.92 Million | $-36.83 Million | -0.485x | -274.02% |
| 2000-12-31 | $116.70 Million | $-15.13 Million | -0.130x | +50.34% |
| 1999-12-31 | $51.70 Million | $-13.50 Million | -0.261x | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a sap… Read more